GENSCRIPT BIO announced that, under the collaboration and license agreement signed on December 21, 2017, between Legend Biotech Corporation (an associate of the company whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) and Janssen Biotech, Inc., CARVYKTI® generated approximately $597 million in net trade sales for the quarter ended March 31, 2026.